Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

Schizophrenia Research

Volumn 132, Issue 2-3, 2011, Pages 101-107

  Potkin, Steven G ^a   Ogasa, Masaaki ^b,c   Cucchiaro, Josephine ^b   Loebel, Antony ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Antipsychotic; Atypical; Lurasidone; Schizophrenia; SM 13496; Ziprasidone

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESZOPICLONE; LURASIDONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOLPIDEM;

ADULT; AGED; AKATHISIA; ANXIETY; ARTHRALGIA; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOCHOLESTEROLEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUSCLE SPASM; NAUSEA; OUTPATIENT; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CHOLESTEROL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; OUTPATIENTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 80054080823     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.04.008     Document Type: Article

References (27)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. Allison D.B., Mentore J.L., He,o M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156:1686-1696.
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) Washington 2000, American Psychiatric Press, Inc., DC.
5. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
6. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999, 20:491-505.
7. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004, 24:192-208.
8. Enomoto T., Ishibashi T., Tokuda K., et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res. 2008, 186:197-207.
9. Geodon, 2008. [prescribing information]. New York, NY: Pfizer Inc.
10. Guy W.A. Abnormal Involuntary Movement Scale (AIMS). US Department of Health, Education, and Welfare Pub. No. (ADM) 76-338 1976, 534-537. revised, NIMH, Rockville, MD.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Pub. No. (ADM) 76-338 1976, 217-222. revised, NIMH, Rockville, MD.
12. Harrigan E.P., Miceli J.J., Anziano R., Watsky E., Reeves K.R., Cutler N.R., Sramek J., Shiovitz T., Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 2004, 24:62-69.
13. Harvey, P.D., Ogasa, M., Cucchiaro, J., Loebel, A., Keefe, R.S.E., 2011. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schiz Res. 127, 188-194.
14. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., Matsumoto K., Nishikawa H., Ueda Y., Toma S., Oki H., Tanno N., Saji I., Ito A., Ohno Y., Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010, 334:171-181.
15. Ishiyama T., Tokuda K., Ishibashi T., et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007, 572:160-170.
16. Kay S.R., Fiszbein A., Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
17. Keefe R.S., Poe M., Walker T.M., Kang J.W., Harvey P.D. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am. J. Psychiatry 2006, 163:426-432.
18. Latuda [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals, Inc; 2010.
19. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
20. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166:152-163.
21. Matsumoto Y., Matsumoto K., Horisawa T., Yabuuchi K., Ishibashi T. Lurasidone is associated with anxiolytic and antidepressant effects in rodent models. Poster presentation at the 162nd Annual Meeting of the American Psychiatric Associating 2009, May 16-21, San Francisco.
22. Meltzer, H.Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu J., Kalali, A.H., Schweizer, E., Pikalov, A., Loebel, A., 2011. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo and olanzapine-controlled study. Am. J. Psychiatry June 15 [Epub ahead of print].
23. Morrato E.H., Newcomer J.W., Allen R.R., Valuck R.J. Prevalence of baseline serum glucose and lipid testing in users of second generation antipsychotic drugs: a retrospective, population based study of Medicaid claims data. J. Clin. Psychiatry 2008, 69:316-322.
24. Nakamura M., Ogasa M., Guarino J., Phillips D., Severs J., Cucchiaro J., Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009, 70:829-836.
25. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
26. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165:203-213.
27. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.